San Diego Life Sciences Roundup: Qualcomm, Amylin, Organovo & More

(Page 2 of 2)

food enzymes and oilseed processing business. DSM acquired assets last year from San Diego’s Verenium in a deal valued at $37 million.

—GlaxoSmithKline (NYSE: GSK), AstraZeneca (NYSE: AZN), Cubist Pharmaceuticals (NASDAQ: CBST), and Japan’s Astellas have reportedly expressed interest in buying San Diego’s Optimer Pharmaceuticals (NASDAQ: OPTR). Optimer Pharmaceuticals‘ headquarters moved from San Diego, where the company was founded, to New Jersey as former Pfizer CEO Henry McKinnell took over as CEO.

—San Diego’s Genalyte said it has a new diagnostic test to determine if a therapy is triggering an unwanted immune response to a drug. The company says anti-drug antibodies can reduce the efficacy of a drug and cause a variety of harmful effects. Genalyte says its assay streamlines testing for both mouse and human samples, “providing real-time detection without the use of dyes, fluorescent probes or radioactive labels.”

—San Diego’s Organovo, which currently trades over the counter, has signaled plans to apply for a listing on the New York Stock Exchange or Nasdaq exchange. In a statement, the regenerative medicinecompany says its board approved a change in the end of Organovo’s fiscal year. Organovo’s current fiscal year began on April 1st and will end on March 31st each year.

Single PageCurrently on Page: 1 2 previous page